A Multi-centre Randomised Clinical Trial of Biomarker-driven Maintenance Treatment for First-line Metastatic Colorectal Cancer (MODUL)

Trial Profile

A Multi-centre Randomised Clinical Trial of Biomarker-driven Maintenance Treatment for First-line Metastatic Colorectal Cancer (MODUL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Vemurafenib (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MODUL
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Feb 2017 This trial has been suspended in Netherlands as per European Clinical Trials Database record.
    • 13 Jul 2016 This trial was suspended in Netherlands, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top